| Outcome Measures: |
Primary: 24 h Urine sodium excretion (mmol/day), At baseline (day 0), before treatment with IMP (day 5), and after completion of 4 days treatment with IMP (day 9).|Water excretion (L), 24 h urine collection, At baseline (day 0), before treatment with IMP (day 5), and after completion of 4 days treatment with IMP (day 9).|Total Body Water (L), Measured by Body Composition Monistor, At baseline (day 0), before treatment with IMP (day 5), and after completion of 4 days treatment with IMP (day 9).|Home blood pressure, At baseline (day 0), before treatment with IMP (day 5), and after completion of 4 days treatment with IMP (day 9). | Secondary: Urine protease activity: zymography + protease activity, At baseline (day 0), before treatment with IMP (day 5), and after completion of 4 days treatment with IMP (day 9).|Tubular complement activation, Urine C3a, MAC-sC5b-9, C3dg, MBL, At baseline (day 0), before treatment with IMP (day 5), and after completion of 4 days treatment with IMP (day 9).|Urine microvesicles: gammaENaC cleavage, At baseline (day 0), before treatment with IMP (day 5), and after completion of 4 days treatment with IMP (day 9).|Urine microvesicles: complement deposition, At baseline (day 0), before treatment with IMP (day 5), and after completion of 4 days treatment with IMP (day 9).|24 hours urine albumin excretion (mg/day), At baseline (day 0), before treatment with IMP (day 5), and after completion of 4 days treatment with IMP (day 9).|Plasma concentration of renin, NT-proBNP, angiotensin II and aldosterone, At baseline (day 0), before treatment with IMP (day 5), and after completion of 4 days treatment with IMP (day 9).
|
